成都弘基生物

Chengdu Hongji Biotech is a Chinese biotechnology company specializing in the development of innovative gene therapies, with a primary focus on ophthalmic diseases. The company leverages its proprietary Adeno-Associated Virus (AAV) vector platform to create long-lasting treatments for conditions such as neovascular age-related macular degeneration (nAMD) and diabetic macular edema. By utilizing gene delivery systems to express therapeutic proteins directly within the eye, Hongji Biotech aims to reduce the burden of frequent intravitreal injections for patients. The company is currently advancing its lead candidates through the IND-enabling and early clinical stages in China.